-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Pyruvate Kinase Activators: Targeting Red Cell Metabolism in Sickle Cell Disease

Program: Education Program
Session: Energizing the Red Cell: Pyruvate Kinase Activators for Treatment of Hereditary Hemolytic Anemias
Hematology Disease Topics & Pathways:
Research, clinical trials, Sickle Cell Disease, Translational Research, Clinical Research, Hemoglobinopathies, drug development, Diseases, Therapies, metabolism, Biological Processes
Monday, December 11, 2023, 10:30 AM-11:45 AM

Eduard J. Van Beers, MD, PhD

Center for Benign Hematology, Thrombosis and Hemostasis - Van Creveldkliniek, University Medical Centre Utrecht, Utrecht, Netherlands

Disclosures: Van Beers: RR Mechatronics: Research Funding; Novartis AG: Research Funding; Pfizer, Inc.: Research Funding; Agios Pharmaceuticals, Inc. Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding.

OffLabel Disclosure: IT discusses the clinical development of several PK activators for which there is no label yet. That is the topic of the talk...